U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282093) titled 'Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment' on Nov. 19.
Brief Summary: This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
Pharmacokinetic
Olverembatinib
Intervention:
DRUG: Olverembatinib 20mg
orally after meal, single dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ascentage Pharma Group Inc.
Disclaimer: Curated by HT Syndication....